News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alcobra (ADHD) To Present New Data For Metadoxine Extended Release (MDX) At Upcoming Meetings



4/24/2014 9:01:01 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TEL AVIV, Israel, April 24, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, will present new data for Metadoxine Extended Release (MDX or MG01CI) at the upcoming 167th Annual Meeting of the American Psychiatric Association (APA) and 69th Annual Scientific Meeting of the Society of Biological Psychiatry (SOBP), both held in New York, NY. Details of the presentations are as follows:

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
Alcobra
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES